Gastric Cancer: Enhanced Clinical Decision-Making Via Molecular Profiling

Through expert-led discussions, clinicians will learn how to engage multidisciplinary teams (MDTs) to enhance gastroesophageal (GE) cancer care coordination, from diagnosis to treatment. The program will emphasize the use of molecular profiling and biomarker testing to guide personalized treatment plans, focusing on actionable mutations and key biomarkers in GE cancers. Through case-based scenarios, faculty will explore how key molecular findings and patient/tumor characteristics influence treatment decisions, striving towards optimized outcomes for patients with GE cancers.

ACTIVITY CHAIR:

Samuel J. Klempner, MD

Director, Gastroesophageal Medical Oncology
Associate Professor, Harvard Medical School
Mass General Cancer Center
Boston, MA

FACULTY:

Yelena Y. Janjigian, MD

Attending Physician
Professor, Weill Cornell Medical College
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Target Audience

The intended audience for this activity is primarily US-based community oncologists and hematologist-oncologists involved in the management of patients with solid tumor cancers, and secondarily, additional members of community oncology care teams.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Use appropriate methods for biomarker testing to better guide clinical decision-making.
• Individualize treatment plans for patients with advanced solid tumors based on the latest evidence as well as patient and tumor characteristics.
• Use MDT strategies to improve coordination of care for patients undergoing anti-cancer therapy.

Accreditation / Designation of Credit

In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This enduring material is approved for 1 year from the date of original release, December 31, 2024, to December 30, 2025.

How to Participate in This Activity and Obtain CE Credit

To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.